Liposomal Doxorubicin
Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound
... AP-1 liposomal doxorubicin and a similar approach using untargeted liposomal ...of doxorubicin was significantly greater at the tumor site with the untargeted liposomal ...
10
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
... Results: Mice receiving high doses of doxorubicin died early during follow-up. Lowering the dose improved survival but did not markedly impair cardiac function on echocardiography and caused only limited fibrosis ...
5
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
... pegylated liposomal doxorubicin), all of which are considered ...Pegylated liposomal doxorubicin (PLD) is a liposomal form of the anthracycline antibiotic ...conventional ...
6
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
... Abstract: Pegylated liposomal doxorubicin (PLD) has been widely used to treat cancer. The adverse effects of PLD noted in clinical practice, especially hand-foot syndrome (HFS), are regarded as unique, and ...
7
Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin
... It is important to point out the meaning of our results. It has been pointed out that a network of highly cited papers is related to the paradigmatic structure of a specific research field [34]. A literature network ...
10
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer
... pegylated liposomal doxorubicin (PLD) for brain metastasis of breast ...of doxorubicin accumulated in the normal brain tissues and tumor tissues with/without FUS hyperthermia were measured using ...
10
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
... somal doxorubicin”, “Doxil” “Myocet”, “Doxorubicin”, “Daunorubicin”, “Epirubicin”,“Mitoxantrone”,and “Idaru- ...“liposomal doxorubicin” compared with “Doxorubicin” was searched using ...
9
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
... L-DOX, liposomal doxorubicin; LveF, left ventricular ejection fraction; ORR, overall response rate; OS, overall survival; pCR, pathological complete response; pCRT, total pathological complete response; ...
11
New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
... decades doxorubicin, alone or in combination with other cytotoxic agents, has been a mainstay of systemic therapy for ...recently liposomal formulations of doxorubicin have been developed which ...
18
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival
... Abstract: Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11–12 months after diagnosis. A case of a 67-year-old male who ...
6
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
... Abstract: Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the ...
7
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
... Because of its signifi cant activity in the relapsed/ refractory setting, with manageable and non-overlapping toxicities, PLD + B is also being evaluated as induction therapy prior to ASCT. This Cancer and Leukemia Group ...
10
Original Article Efficacy and safety of pegylated liposomal doxorubicin for multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
... The following electronic databases were searched: MEDLINE/Ovid (from 1946 to August Week 4 2016), Embase/Ovid (from 1974 to September 2016), the Cochrane Central Regi- ster of Controlled Trials (The Cochrane Library ...
13
<p>Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin</p>
... pegylated liposomal doxorubicin with carbo- platin (CD) showed superiority over paclitaxel and carboplatin (CP) in progression-free survival (PFS) and less overall ...
7
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
... Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes coated with methoxypoly (ethylene ...Unlike doxorubicin, ...
7
Pegylated liposomal doxorubicin in ovarian cancer
... of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical ...utility. Liposomal doxorubicin is devoid of the cardiac ...
12
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
... (PEG) liposomal doxorubicin is a formulation of doxorubicin in which the drug is encapsulated in PEG-coated ...cholesterol. Doxorubicin, which is a cytotoxic antibiotic, is an anthracycline ...
6
Pegylated liposomal doxorubicin in the management of ovarian cancer
... pegylated liposomal doxorubicin (PLD), whose unique formulation, which entraps conventional doxorubicin in a bilayer lipidic sphere surrounded by a polyethylene glycol layer, prolongs the persistence ...
21
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
... patients are limited [5]. The most widely used approved drugs for this indication are topotecan and pegylated liposomal doxorubicin (PLD). A randomized phase 3 trial comparing these agents showed modest ...
11
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
... Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M: Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplati[r] ...
7